SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law (NASDAQ:SRPT)

Core Viewpoint - Sarepta Therapeutics, Inc. is under investigation for potential violations of federal securities laws related to the safety profile of its product Elevidys, which has been linked to fatal acute liver failure in patients [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [2]. Incident Timeline - On March 18, 2025, Sarepta announced the death of a patient treated with Elevidys due to acute liver failure, resulting in a stock price drop of $27.81, or over 27%, from $101.35 to $73.54 per share [3]. - Following a second patient death on June 15, 2025, Sarepta suspended certain shipments of Elevidys and paused dosing in an ongoing clinical trial, leading to a further stock decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [3]. Legal Implications - Investors in Sarepta may have legal options available and are encouraged to submit their information to the investigating law firm, Bleichmar Fonti & Auld LLP, which operates on a contingency fee basis [4][5]. Law Firm Background - Bleichmar Fonti & Auld LLP is a prominent international law firm specializing in securities class actions and shareholder litigation, recognized for recovering significant amounts for clients in past cases [5].